Clementia Pharm (NASDAQ:CMTA) – Equities research analysts at Wedbush issued their Q3 2017 EPS estimates for Clementia Pharm in a report released on Monday. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.30) per share for the quarter. Wedbush has a “Outperform” rating and a $26.00 price objective on the stock. Wedbush also issued estimates for Clementia Pharm’s Q4 2017 earnings at ($0.31) EPS, FY2018 earnings at ($1.48) EPS, FY2019 earnings at ($1.55) EPS, FY2020 earnings at ($1.62) EPS and FY2021 earnings at ($1.74) EPS.
A number of other analysts also recently issued reports on the stock. Morgan Stanley started coverage on shares of Clementia Pharm in a report on Monday. They set an “overweight” rating and a $27.00 price objective for the company. Leerink Swann started coverage on shares of Clementia Pharm in a report on Monday. They set an “outperform” rating for the company.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Clementia Pharm’s Q3 2017 Earnings (CMTA)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://ledgergazette.com/2017/08/30/equities-analysts-offer-predictions-for-clementia-pharms-q3-2017-earnings-cmta.html.
Shares of Clementia Pharm (NASDAQ:CMTA) opened at 16.10 on Wednesday. The company’s 50-day moving average price is $14.97 and its 200-day moving average price is $14.97. Clementia Pharm has a 12-month low of $15.05 and a 12-month high of $18.95. The firm’s market capitalization is $491.48 million.
About Clementia Pharm
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharm Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clementia Pharm and related companies with MarketBeat.com’s FREE daily email newsletter.